Physician profile
Michael R Wasserman
NPI 1992748537
$81,919.07
in general payments reported to CMS, 2019-2025
7 companies · $7,676 in 2025
The $7,676 reported for 2025 was more than what 98% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $17K · 2021: $12K · 2022: $11K · 2023: $12K · 2024: $10K · 2025: $7,676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $30K · Food and Beverage: $386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $29,500.00 |
| Food and Beverage | $386.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $75,503.01 | 2019-2025 | |
| Eisai INC. | $5,766.98 | 2020 | |
| Acadia Pharmaceuticals INC | $207.32 | 2019-2023 | Nuplazid |
| Astellas Pharma US INC | $172.60 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $103.63 | 2023-2025 | Rexulti |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $96.25 | 2025 | Rexulti |
| Sumitomo Pharma America, INC. | $69.28 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wasserman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.